FOR RESEARCH USE ONLY - NOT FOR HUMAN CONSUMPTION.
ARA 290 Research Review
ARA 290 research review begins with a distinction that is often lost in abbreviated product descriptions: ARA 290, also called cibinetide in published literature, is a defined synthetic peptide used to investigate erythropoietin-derived signaling concepts. It is not erythropoietin, and results associated with one should not be transferred automatically to the other. For Research Use Only - Not for Human Consumption.
The research interest in ARA 290 centers on a short sequence derived from the B-helix region of erythropoietin. Published work has examined receptor hypotheses, cell-signaling activity, inflammatory signaling markers, and functional observations in controlled preclinical models. That literature is useful, but it is heterogeneous. Experimental species, assay endpoints, exposure conditions, and peptide preparation vary substantially across studies.
For laboratory buyers, identity confirmation and batch documentation should come before interpretation of any paper. A peptide labeled ARA 290 should be evaluated as a specific chemical entity with a stated sequence, analytical profile, and lot-specific certificate of analysis.
> Compliance Notice
>
> ARA 290 is supplied exclusively for laboratory research use. It is not for human consumption, clinical use, veterinary use, diagnostic use, or personal administration. No information on this page constitutes dosing, administration, or medical guidance.
Chemical Identity and Analytical Considerations
ARA 290 is commonly described as an 11-amino-acid peptide corresponding to an erythropoietin B-helix-derived sequence. The reported sequence is pGlu-Glu-Gln-Leu-Glu-Arg-Ala-Leu-Asn-Ser-Ser, often abbreviated as pQEQLERALNSS. The N-terminal pyroglutamate residue is material to the identity of the peptide and should be considered when comparing vendor specifications, mass data, and analytical methods.
Reported molecular weight is approximately 1,258 Da for the peptide free base, though the practical reported mass can differ according to counterion, salt form, hydration state, and the analytical convention used. A specification sheet should identify these variables rather than presenting molecular weight as an isolated number.
For research workflows, reverse-phase HPLC and mass spectrometry address different questions. HPLC estimates chromatographic purity under the stated method conditions. Mass spectrometry supports molecular identity by assessing the expected mass-to-charge signal. Neither result alone establishes every aspect of material quality. A complete release package may also include appearance, residual solvent limits, water content, endotoxin testing where relevant to the planned assay, and stability information.
A stated purity threshold such as >99% by HPLC is a meaningful starting specification, not a substitute for reviewing the actual batch record. Researchers should confirm that the COA lot number matches the vial label and that the chromatogram, method details, and analytical date are available for review.
What the Published Literature Examines
The foundational literature describes ARA 290 as a non-erythropoietic peptide designed to investigate signaling distinct from erythropoiesis. In a widely cited paper, Brines and colleagues evaluated an erythropoietin-derived peptide across experimental systems and framed the work around a proposed tissue-protective receptor complex. See Proceedings of the National Academy of Sciences, 2008, DOI: 10.1073/pnas.0711084105.
Subsequent work has examined ARA 290 in cell culture, rodent models, and limited investigator-led human research settings. These studies have measured variables such as cytokine-associated signals, sensory testing endpoints, and laboratory biomarkers. They do not establish that a research peptide is appropriate for consumption or clinical application, and they should not be read as product-performance claims.
A 2013 publication in PLOS ONE evaluated cibinetide in a defined research population and collected mechanistic and exploratory outcome data. DOI: 10.1371/journal.pone.0081843. The study is relevant primarily because it illustrates how translational research can generate signals that require replication, protocol-specific interpretation, and separation from preclinical findings.
A later randomized research study reported in Neurology evaluated ARA 290 under a controlled protocol. DOI: 10.1212/WNL.0000000000001525. For a laboratory reviewer, the main takeaway is not a single endpoint. It is that peptide literature must be assessed in context: formulation, route, study population, sample size, controls, statistical plan, and endpoint selection all influence what can reasonably be inferred.
Why Literature Results Do Not Transfer Directly
Short peptides can be sensitive to handling conditions. Oxidation, deamidation, adsorption to surfaces, aggregation, freeze-thaw exposure, and solvent selection can alter the material presented to an assay. A published study using a particular preparation cannot validate a separate, undocumented lot.
The same caution applies to concentration. Nominal concentration calculated from vial labeling may not equal active concentration in a final experimental system. Researchers should account for reconstitution volume, salt form, solution pH, excipient compatibility, container adsorption, and assay-specific recovery. These are standard experimental controls, especially when comparing results between peptide suppliers or between lots.
Proposed Mechanism in Laboratory Models
The most frequently discussed mechanism involves a proposed heteromeric receptor system containing the erythropoietin receptor and CD131, also known as the beta common receptor. This receptor model is often referred to in the literature as the innate repair receptor. In experimental settings, ARA 290 has been used to investigate downstream signaling networks associated with JAK2, STAT-family signaling, PI3K/Akt pathways, NF-kB-related transcriptional activity, and inflammatory mediator expression.
That model should be treated as a research framework rather than settled fact. Receptor expression can vary by cell type, species, tissue preparation, and assay method. Apparent signaling differences may also reflect peptide concentration, incubation time, culture conditions, or differences in receptor detection reagents. Well-designed work should include vehicle controls, positive controls where justified, independent confirmation of receptor expression, and lot-level peptide characterization.
A useful ARA 290 research review therefore asks two separate questions. First, what was observed in the specific model? Second, how convincingly does the experimental design support the proposed mechanism? Those are not the same question.
Quality Controls for ARA 290 Research Material
For experienced buyers, the purchasing decision should be documentation-led. The minimum expectation is a batch-specific COA rather than a generic sample report. The COA should identify the product name, lot number, test date, purity method, and mass-confirmation result. Ideally, the HPLC trace and mass spectrum are available as supporting records.
Peptide Source positions ARA 290 as a research-grade material with a stated 99% purity standard, manufacturer documentation, and additional third-party verification. Before introducing any lot into a study, researchers should download or request the corresponding batch documentation and verify the lot identifier against the received vial.
Storage and handling requirements must follow the lot-specific documentation. Lyophilized peptide stability and solution stability are not interchangeable. A controlled record of receipt date, storage condition, reconstitution solvent, aliquoting procedure, and freeze-thaw history can prevent avoidable variation in downstream data.
Documentation Questions Worth Asking
A supplier should be able to answer whether the stated purity was determined by HPLC or UPLC, whether identity was confirmed by mass spectrometry, and whether the displayed COA is specific to the inventory lot. Researchers may also need to know the counterion form, residual solvent specification, packaging configuration, and whether endotoxin testing was performed for the intended experimental context.
If those records are unavailable, the limitation should be documented in the study record. High reported purity does not correct for an uncertain identity, incomplete chain, mismatched lot, or unsuitable handling history.
Practical Reading of the Evidence
ARA 290 is a focused research tool, not a broad conclusion packaged in a vial. Its published literature supports continued investigation of erythropoietin-derived peptide signaling, while also showing why assay design and source verification matter. The strongest use of the evidence is to inform a testable hypothesis, define appropriate controls, and identify conditions that should be independently replicated.
For Research Use Only - Not for Human Consumption. Any ARA 290 research program should close the loop between the paper being cited, the exact peptide identity being used, and the batch-specific analytical record supporting that material.
Prepared by the Research Team at The Peptide Source.